OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018)

BIOGRAPHICAL SKETCHProvide the following information for the Senior/key personnel and other significant contributors.

Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Steven P. LaRosa, M.D.

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Staff Physician , Lahey infectious Disease, Beverly

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE(if

applicable)

Completion Date

MM/YYYYFIELD OF STUDY

Boston College, Chestnut Hill, MABoston University School of Medicine, Boston, MACleveland Clinic FoundationMassachusetts General Hospital

B.S.M.D.NANA

05/198805/199206/199606/1998

BiologyMedicineInternal MedicineInfectious Disease

A. Personal Statement

B. Positions and Honors

Positions and Employment1998-2001 Clinical Research Physician, Lilly Research Laboratories, Indianapolis, IN2001-2004 Staff Physician, Department of Infectious disease, Cleveland Clinic Foundation,

Cleveland, OH2004-2011 Assistant Professor of Medicine, The Warren Alpert Medical School of Brown University,

Providence Rhode Island2011-2012 Associate Professor of Medicine, Texas A&M Health Science Ctr., College of Medicine,

Temple Texas2012- Staff Physician, Infectious Disease, Lahey Health System, Beverly, MA

Other Experience and Professional Memberships1996- Member, Infectious Disease Society of America1998- Member, Society of Critical Care Medicine2003 Member, Clinical Evaluation Committee, BAR03 Phase III Study of PAFase in Severe

Sepsis2002-2005 Member, Clinical Evaluation Committee, Phase II trial of E5564 in Severe Sepsis2004-2011 Director, Ocean State Clinical Coordinating Center2004-2007 Member, Clinical Evaluation Committee, TFP008 Study2005 Member, Clinical Evaluation Committee, TFP007 Study2007-2010 Co-Chair, Clinical Evaluation Committee, ACCESS Study2008-1010 Member, Data Safety Monitoring Board, Phase I –GED1-102-ADS2012- Medical Director, Antimicrobial Stewardship, Beverly Hospital

2015- Member, Data Safety Monitoring Board, A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-B)

2015- Member, Data Monitoring Committee, Phase Ib/2a Study – Anti-PD –L1 monoclonal antibody (BMS-936559) for Severe Sepsis

2015- Member, Event Adjudication Committee, A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus aureus 4-antigen (SA4Ag) in Adults Undergoing Elective Posterior Instrumental Lumbar Spinal Fusion Procedures

Honors1992 Alpha Omega Alpha Honor Society2005 Dean’s Teaching Excellence Award, Brown Medical School2006 Dean’s Teaching Excellence Award, Brown Medical School2008-2009 Brown Infectious Diseases Fellowship Steven M. Opal Teaching Award2009- Castle Connolly, Top Doctors, Infectious Disease

C. Contribution to Science

D. Additional Information: Research support and/ or Scholastic Performance

Ongoing Research SupportDARPA-BAA-11-30 2015-Dialysis Like Therapeutics (DLT)Role: Consultant

Completed Research Support

Novartis Pharmaceuticals LaRosa(PI) 5/01/2004-07/21/2008Clinical Coordinating Center for TFP008: Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-Arm Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) Administration in Subjects with Severe Community Acquired Pneumonia. Role: Director of Clinical Coordinating Center

Eisai LaRosa(PI) 12/01/2005-01/31/2011Clinical Coordinating Center for E5564-G000-301: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis. Role: Director of Clinical Coordinating Center

Agennix Incorporated LaRosa (PI) 03/01/2008- 07/2009 Clinical Coordinating Center for LF-0801: A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis. Role: Director of Clinical Coordinating Center

AstraZeneca Pharmaceuticals LaRosa (PI) 11/01/2009-03/31/2011Clinical Coordinating Center for A Multicenter, Randomized, Double-Blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two or Three Dosing Regimens of Intravenous Infusions of CytoFab™ (AZD9773) in Adult Patients with Severe Sepsis. Role: Director of Clinical Coordinating Center

Agennix Incorporated LaRosa (PI) 11/01/2010-05/31/2011

Clinical Coordinating Center for OASIS: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis. Protocol No. LF-0802Role: Director of Clinical Coordinating Center